Iterum Therapeutics

News

Iterum has launched Orlynvah as a treatment for uncomplicated urinary tract infections (uUTIs), the first oral option in the go-to penem class.

Oncology

At Reuters Pharma USA this week, Boehringer Ingelheim's Vicky Brown spoke with us about the company's recent approval for Hernexeos in NSCLC.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.